MA-DEBIOPHARM
Genialis, the RNA-biomarker company, and Debiopharm, a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, have reached an agreement to define and discover biomarkers within the DNA Damage Repair (DDR) biology space to predict the clinical benefit of one or more drugs in Debiopharm’s pipeline. The initial phase kicked off this month, deploying Genialis’ biology-first, machine learning-enabled ResponderIDTM framework to develop predictive biomarkers for DDR-directed therapies.
“Debiopharm continues to lead the oncology field in adopting artificial intelligence solutions at various stages across our preclinical and clinical development programs. Genialis’ expertise and cutting-edge technologies are an ideal fit to help us make the smartest translational decisions and advance our drugs to reach the right patients,” said Bertrand Ducrey, CEO of Debiopharm.
Many cancers exhibit deficiencies in one or more DNA damage response pathways. Various classes of approved and investigational drugs aim to exploit known sensitivities; however, the heterogeneous biology of DNA damage response means that one drug only fits some, and combinations may prove essential. Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism.
“DNA damage response is among the most exciting biological domains of cancer drug development today and an area in which Debiopharm is working on several exciting molecules,” said Carolina Haefliger, Head of Translational Medicine at Debiopharm. “Genialis’ biology-first approach allows us to collaborate in a truly scalable way, incorporating novel AI-based solutions in our programs.”
Using biomarkers increases the odds of advancing an oncology clinical asset to the next trial phase by 5-12 fold1. However, post-approval, many of the best drugs achieve clinical benefit in only 30-40 percent of patients, and even those existing targeted therapies considered successful and supported by a biomarker can benefit from further refinement of patient tailoring strategies.
“Genialis’ RNA biomarkers have proved especially well-suited to support the development of new drugs targeting complex biological systems,” said Mark Uhlik, Vice President of Biomarker Discovery at Genialis. “Debiopharm is working on some really promising molecules, and Genialis' biomarkers will help ensure these drugs have the best possible chance of clinical success.”
Genialis is based in Boston, Mass., and will attend PMWC in Santa Clara, Calif., from January 23-25, 2024. To request a meeting or for more information on ResponderID, please email biomarkers@genialis.com or visit www.genialis.com.
Debiopharm is headquartered in Lausanne, Switzerland, and will be presenting at the 7th Annual DDR Inhibition Conference in Boston from January 29-30, 2024.
About DNA-Damage Repair (DDR)
When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells use their hyperactive DDR response to divide and grow uncontrollably, which promotes cancer expansion. Inhibition of DDR, particularly in combination with other anticancer agents, induces an overall arrest in the uncontrollable cancer cell cycle. This ultimately activates a self-destruction program in cancer cells. DDR inhibitors are currently being tested in preclinical and clinical studies.
About Genialis
Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families and communities. ResponderID™, Genialis’ machine-learning-driven disease modeling framework, delivers actionable biomarkers and optimally positions novel drugs to accelerate translational research, streamline drug development and ensure the best possible clinical care. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data. For more information, please visit www.genialis.com
About Debiopharm
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to develop tomorrow’s standard of care to cure cancer & infectious diseases and improve patient quality of life. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment. The company believes in the future digital biology where AI is the main engine for this transformation.
For more information, please visit www.debiopharm.com
1 Parker JL et al, 2021: doi:10.1002/cam4.3732
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240125413015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Marjan and RAK Hospitality Holding Announce Landmark Merger to Shape The Future Of Ras Al Khaimah As A Global Destination for Lifestyle and Investment22.10.2025 17:17:00 CEST | Press release
Marjan, the master developer of freehold properties in Ras Al Khaimah, and RAK Hospitality Holding, the government-owned investment and development arm in the Emirate, have announced a landmark strategic merger to create a unified entity operating under Marjan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022275206/en/ Marjan and RAK Hospitality Holding Announce Landmark Merger To Shape The Future Of Ras Al Khaimah As A Global Destination For Lifestyle And Investment (Photo: AETOSWire) This merger combines world-class hospitality expertise with visionary land development strategies to form a dynamic future-ready organization. Marjan will integrate real estate development, hospitality operations, and lifestyle experiences under one umbrella, positioning itself as one of the largest real estate developers in the UAE and the leading master developer in the Northern Emirates. Announcing the merger, His Highness Sheikh Ahmed
Venture Global Statement on CP2 Final Approval22.10.2025 16:33:00 CEST | Press release
The U.S. Department of Energy issued the final non-FTA export authorization for Venture Global’s CP2 facility in Cameron Parish, Louisiana. Venture Global CEO Mike Sabel issued the following statement: “Venture Global is grateful for the Trump Administration’s final approval of CP2, a critical project that will supply American allies with low-cost LNG for decades, support thousands of jobs and greatly benefit the U.S. balance of trade. The CP2 project construction is well underway and we look forward to continue advancing the project safely and quickly to bring new LNG to the global market at a record pace beginning in 2027.” About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated bus
British Arab Commercial Bank Partners With Volante Technologies to Modernize Payments Infrastructure With PaaS22.10.2025 15:38:00 CEST | Press release
Volante’s cloud-native platform to unify BACB’s payment operations across SWIFT, CHAPS, Faster Payments, BACS, and more Volante Technologies, the global leader in Payments as a Service (PaaS), today announced a new partnership with British Arab Commercial Bank (BACB), to modernize the bank’s payment processing infrastructure and replace legacy systems with a cloud-native platform. BACB will use Volante’s PaaS solution to automate and streamline the entirety of its payments volumes across multiple payment schemes, including SWIFT MT/ISO 20022, CHAPS, Faster Payments, BACS, and internal transfers. Volante’s solution enables BACB to move beyond legacy systems and manual processes, empowering the bank to raise straight-through processing rates and continue to provide a first-class service to its customers. BACB is an international wholesale bank, with $4.4 billion in assets, who provide a range of trade solutions to clients trading in and out of developing markets, across Africa and the Mi
Qualcomm Schedules Fourth Quarter and Fiscal 2025 Earnings Release and Conference Call22.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its fourth quarter and fiscal 2025 on Wednesday, November 5, 2025, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its fourth quarter and fiscal 2025 results which will be broadcast live on November 5, 2025, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/investor-events/default.aspx. An audio replay will be available at https://investor.qualcomm.com/news-events/investor-events/default.aspx and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and internat
XPRIZE and Avanci Launch Partnership to Provide Innovators with IP and Licensing Expertise22.10.2025 15:00:00 CEST | Press release
Collaboration ensures innovators benefit from critical resources to protect and advance breakthrough solutions XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s greatest challenges, and Avanci, the independent global leader in one-stop IP licensing platforms, today announced a partnership to empower XPRIZE innovators. For more than three decades, XPRIZE competitions have ignited bold solutions that ripple far beyond the competition itself to transform industries, inspire new technologies, and build an extraordinary global ecosystem of innovators dedicated to problem solving. This partnership with Avanci ensures that XPRIZE teams and alumni have access to the expertise and resources they need to protect, scale, and amplify their impact in the real world through access to Avanci’s expertise and experience in intellectual property (IP) protection and licensing. Tailored support from Avanci will help those entrepreneurs protect their breakthro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom